{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:05:41Z","timestamp":1751965541311},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57080","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T23:58:25Z","timestamp":1711583905000},"source":"Crossref","is-referenced-by-count":1,"title":["Comorbid Ankylosing Spondylitis and Systemic Lupus Erythematosus: A Therapeutic Challenge"],"prefix":"10.7759","author":[{"given":"Charles  E","family":"DeBoisblanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program","volume":"66","author":"Somers EC","year":"2014","unstructured":"Somers EC, Marder W, Cagnoli P, et al.. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Rheumatol. 2014, 66:369-78. 10.1002\/art.38238","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22683","article-title":"Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999","volume":"57","author":"Somers EC","year":"2007","unstructured":"Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum. 2007, 57:612-8. 10.1002\/art.22683","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25933-4","article-title":"Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010-2015 and estimated differences according to income status","volume":"8","author":"Park JS","year":"2018","unstructured":"Park JS, Hong JY, Park YS, Han K, Suh SW. Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010-2015 and estimated differences according to income status. Sci Rep. 2018, 8:7694. 10.1038\/s41598-018-25933-4","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel SE","year":"2009","unstructured":"Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009, 11:229. 10.1186\/ar2669","journal-title":"Arthritis Res Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00879-z","article-title":"Sacroiliitis in systemic lupus erythematosus: the rates of involvement of the forgotten joint","volume":"80","author":"Kayacan Erdogan E","year":"2021","unstructured":"Kayacan Erdogan E, Gokcen N, Badak SO, Bicakci YK, Arslan D. Sacroiliitis in systemic lupus erythematosus: the rates of involvement of the forgotten joint. Z Rheumatol. 2021, 80:447-55. 10.1007\/s00393-020-00879-z","journal-title":"Z Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2020.7514","article-title":"Sacroiliitis in systemic lupus erythematosus revisited","volume":"35","author":"Yilmaz N","year":"2020","unstructured":"Yilmaz N, Yazici A, \u00d6zulu T\u00dcrkmen B, Karalok I, Yavuz \u015e. Sacroiliitis in systemic lupus erythematosus revisited. Arch Rheumatol. 2020, 35:254-8. 10.46497\/ArchRheumatol.2020.7514","journal-title":"Arch Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2014.008","article-title":"Coexistence of systemic lupus erythematosus and ankylosing spondylitis: another case report and review of the literature","volume":"1","author":"Tarhan F","year":"2014","unstructured":"Tarhan F, Arg\u0131n M, Can G, \u00d6zmen M, Keser G. Coexistence of systemic lupus erythematosus and ankylosing spondylitis: another case report and review of the literature. Eur J Rheumatol. 2014, 1:39-43. 10.5152\/eurjrheum.2014.008","journal-title":"Eur J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.5.323","article-title":"Concomitant systemic lupus erythematosus and ankylosing spondylitis","volume":"49","author":"Olivieri I","year":"1990","unstructured":"Olivieri I, Gemignani G, Balagi M, Pasquariello A, Gremignai G, Pasero G. Concomitant systemic lupus erythematosus and ankylosing spondylitis. Ann Rheum Dis. 1990, 49:323-4. 10.1136\/ard.49.5.323","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(10)70055-1","article-title":"Coexistence of ankylosing spondylitis and systemic lupus erythematosus","volume":"73","author":"Singh S","year":"2010","unstructured":"Singh S, Sonkar GK, Singh U. Coexistence of ankylosing spondylitis and systemic lupus erythematosus. J Chin Med Assoc. 2010, 73:260-1. 10.1016\/S1726-4901(10)70055-1","journal-title":"J Chin Med Assoc"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1982.00340190183031","article-title":"Ankylosing spondylitis and systemic lupus erythematosus: a rare HLA combination","volume":"142","author":"Nashel DJ","year":"1982","unstructured":"Nashel DJ, Leonard A, Mann DL, Guccion JG, Katz AL, Sliwinski AJ. Ankylosing spondylitis and systemic lupus erythematosus: a rare HLA combination. Arch Intern Med. 1982, 142:1227-8.","journal-title":"Arch Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.012","article-title":"Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: a case report and review of literature","volume":"77","author":"Jiang L","year":"2010","unstructured":"Jiang L, Dai X, Liu J, Ma L, Yu F. Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: a case report and review of literature. Joint Bone Spine. 2010, 77:608-10. 10.1016\/j.jbspin.2010.02.012","journal-title":"Joint Bone Spine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311428461","article-title":"Coexisting systemic lupus erythematosus and ankylosing spondylitis: a case report and review of the literature","volume":"21","author":"Kook MH","year":"2012","unstructured":"Kook MH, Yoo HG, Hong MJ, Yoo WH. Coexisting systemic lupus erythematosus and ankylosing spondylitis: a case report and review of the literature. Lupus. 2012, 21:348-9. 10.1177\/0961203311428461","journal-title":"Lupus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310392420","article-title":"Ankylosing spondylitis in female systemic lupus erythematosus: a rare combination","volume":"20","author":"Mrabet D","year":"2011","unstructured":"Mrabet D, Rekik S, Sahli H, et al.. Ankylosing spondylitis in female systemic lupus erythematosus: a rare combination. Lupus. 2011, 20:777-8. 10.1177\/0961203310392420","journal-title":"Lupus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000108969.21691.5d","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening JJ","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, et al.. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004, 15:241-50. 10.1097\/01.asn.0000108969.21691.5d","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2010.01587.x","article-title":"Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus","volume":"37","author":"Tomasini D","year":"2010","unstructured":"Tomasini D, Mentzel T, Hantschke M, et al.. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol. 2010, 37:1132-9. 10.1111\/j.1600-0560.2010.01587.x","journal-title":"J Cutan Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus","volume":"71","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt M","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Lo\u00ebt X, et al.. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005, 7:R545-51. 10.1186\/ar1715","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2028-2","article-title":"Anti-TNF-alpha-induced lupus","volume":"21","author":"De Bandt M","year":"2019","unstructured":"De Bandt M. Anti-TNF-alpha-induced lupus. Arthritis Res Ther. 2019, 21:235. 10.1186\/s13075-019-2028-2","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz U","year":"2010","unstructured":"Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010, 10:46-50. 10.1016\/j.autrev.2010.07.005","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al.. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68:777-83. 10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel H","year":"2007","unstructured":"Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007, 66:419-21. 10.1136\/ard.2006.054098","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036491","article-title":"Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis","volume":"64","author":"van Denderen JC","year":"2005","unstructured":"van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2005, 64:1761-4. 10.1136\/ard.2005.036491","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al.. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017, 76:978-91. 10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000215.417","article-title":"417 worldwide picture of renal involvement in systemic lupus erythematosus using a big data analytical approach","volume":"4","author":"de Lis Novo MP","year":"2017","unstructured":"de Lis Novo MP, Gand\u00eda M, P\u00e9rez-\u00c1lvarez R, et al.. 417 worldwide picture of renal involvement in systemic lupus erythematosus using a big data analytical approach. Lupus Sci Med. 2017, 4:1-227. 10.1136\/lupus-2017-000215.417","journal-title":"Lupus Sci Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy D","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014, 73:817-23. 10.1136\/annrheumdis-2013-204248","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten D","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al.. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013, 382:1705-13. 10.1016\/S0140-6736(13)61134-4","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin PR","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 59:1796-804. 10.1002\/art.24068","journal-title":"Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros J","year":"2017","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017, 76:1575-82. 10.1136\/annrheumdis-2016-210882","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace DJ","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al.. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 392:222-31. 10.1016\/S0140-6736(18)31363-1","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri M","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, et al.. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023, 401:1011-9. 10.1016\/S0140-6736(22)02546-6","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand EF","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, et al.. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023, 401:1001-10. 10.1016\/S0140-6736(22)02607-1","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al.. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017, 76:1340-7. 10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, et al.. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 392:2378-87. 10.1016\/S0140-6736(18)32463-2","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde D","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al.. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019, 394:2108-17. 10.1016\/S0140-6736(19)32534-6","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-26. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/235638-comorbid-ankylosing-spondylitis-and-systemic-lupus-erythematosus-a-therapeutic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T23:58:28Z","timestamp":1711583908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/235638-comorbid-ankylosing-spondylitis-and-systemic-lupus-erythematosus-a-therapeutic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.57080","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}